Li Di1, Edward H Kerns, Guy T Carter. 1. Principal Research Scientist II Wyeth Research, 865 Ridge Road, Monmouth Jct., Princeton, NJ 08852, USA +1 732 274 4489 ; +1 732 274 4505 ; dil@wyeth.com.
Abstract
BACKGROUND: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties. OBJECTIVE: Define key variables and assays that are essential for determining brain penetration. METHODS: This review covers issues, methods, and strategies for assessing brain penetration of small molecules in drug discovery. RESULTS/ CONCLUSION: Brain penetration is assessed using both initial rate and extent at steady-state. Unbound drug is the active species that exerts pharmacological effects. Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding. Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concentration.
BACKGROUND: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties. OBJECTIVE: Define key variables and assays that are essential for determining brain penetration. METHODS: This review covers issues, methods, and strategies for assessing brain penetration of small molecules in drug discovery. RESULTS/ CONCLUSION: Brain penetration is assessed using both initial rate and extent at steady-state. Unbound drug is the active species that exerts pharmacological effects. Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding. Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concentration.
Authors: Hua Lv; Xiaoping Zhang; Jyoti Sharma; M V Ramana Reddy; E Premkumar Reddy; James M Gallo Journal: AAPS J Date: 2012-11-22 Impact factor: 4.009
Authors: Ahmed Alaofi; Ngoc On; Paul Kiptoo; Todd D Williams; Donald W Miller; Teruna J Siahaan Journal: J Pharm Sci Date: 2016-02 Impact factor: 3.534
Authors: Rui Liang; Daisuke Tomita; Yusuke Sasaki; John Ginn; Mayako Michino; David J Huggins; Leigh Baxt; Stacia Kargman; Maaz Shahid; Kazuyoshi Aso; Mark Duggan; Andrew W Stamford; Elisa DeStanchina; Nigel Liverton; Peter T Meinke; Michael A Foley; Richard E Phillips Journal: ACS Med Chem Lett Date: 2022-02-10 Impact factor: 4.345
Authors: Kevin M Crofton; Arianna Bassan; Mamta Behl; Yaroslav G Chushak; Ellen Fritsche; Jeffery M Gearhart; Mary Sue Marty; Moiz Mumtaz; Manuela Pavan; Patricia Ruiz; Magdalini Sachana; Rajamani Selvam; Timothy J Shafer; Lidiya Stavitskaya; David T Szabo; Steven T Szabo; Raymond R Tice; Dan Wilson; David Woolley; Glenn J Myatt Journal: Comput Toxicol Date: 2022-03-17